FocalTherics (NASDAQ:FOCL) Raised to Hold at Wall Street Zen

FocalTherics (NASDAQ:FOCL) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

FOCL has been the subject of several other research reports. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of FocalTherics in a report on Tuesday, August 25th. Piper Sandler reissued a “neutral” rating and set a $4.00 price objective on shares of FocalTherics in a report on Friday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of FocalTherics in a report on Monday, August 17th. Finally, Mizuho assumed coverage on shares of FocalTherics in a research note on Friday, July 17th. They issued an “outperform” rating and a $15.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $9.67.

FocalTherics Stock Performance

Shares of FocalTherics stock opened at $3.32 on Friday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.40 and a current ratio of 2.63. The company’s fifty day moving average price is $4.23. The stock has a market capitalization of $124.59 million, a price-to-earnings ratio of -3.39 and a beta of -0.02. FocalTherics has a 12 month low of $1.82 and a 12 month high of $6.40.

FocalTherics (NASDAQ:FOCL) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.08. FocalTherics had a negative net margin of 59.77% and a negative return on equity of 223.32%. The company had revenue of $9.83 million during the quarter. Analysts forecast that FocalTherics will post -0.82 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Ryan Rhodes acquired 21,000 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were purchased at an average price of $4.75 per share, with a total value of $99,750.00. Following the transaction, the chief executive officer directly owned 626,649 shares in the company, valued at approximately $2,976,582.75. This represents a 3.47% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Fran Schulz acquired 10,000 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was purchased at an average cost of $4.75 per share, for a total transaction of $47,500.00. Following the transaction, the director owned 15,100 shares in the company, valued at approximately $71,725. The trade was a 196.08% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders purchased 116,000 shares of company stock worth $551,000. Insiders own 10.10% of the company’s stock.

Institutional Investors Weigh In On FocalTherics

A hedge fund recently raised its stake in FocalTherics stock. Rock Springs Capital Management LP raised its holdings in shares of FocalTherics (NASDAQ:FOCL) by 7.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,378,000 shares of the company’s stock after purchasing an additional 91,500 shares during the period. Rock Springs Capital Management LP owned 3.68% of FocalTherics worth $5,126,000 at the end of the most recent quarter. Institutional investors own 62.74% of the company’s stock.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.